CHRISTOPHER KROEGER, M.D., M.B.A.
Chief Executive Officer
Dr. Kroeger joined OvaScience as Chief Executive Officer in September 2017. He brings more than 20 years of experience leading, building and advising development-stage therapeutic and medical device companies, as well as the expertise of a physician and scientist. Most recently, he served as CEO of Cardioxyl Pharmaceuticals. In this role, Dr. Kroeger led a team that produced three investigational new drug candidates and successfully executed six Phase 1 and Phase 2 clinical studies, culminating in the sale of the company to Bristol Myers Squibb for $2.1 billion in total consideration. Prior to Cardioxyl, he led investing efforts as a Partner at The Aurora Funds, a venture capital firm focused on early stage biotechnology and medical device companies. Earlier in his career, he held positions at Genzyme and Decision Resources.
Dr. Kroeger earned his B.A. from Harvard University and his M.D. from Stanford University School of Medicine. He completed his Residency in General Surgery at the Brigham and Women’s Hospital, an affiliate of Harvard Medical School. Dr. Kroeger also holds his M.B.A. from Harvard Business School. He currently serves on the Board of Directors of CardioFocus and Cantex Pharmaceuticals.
JAMES LILLIE, Ph.D.
Chief Scientific Officer
Dr. Lillie joined OvaScience as Chief Scientific Officer in January 2018. He brings extensive cellular biology and biochemistry experience to OvaScience, and leads the Company’s preclinical research and development efforts, including the continued advancement of OvaPrime and OvaTure. Dr. Lillie has more than 25 years of experience driving preclinical research and development across diverse therapeutic areas. He joins OvaScience from Sanofi Genzyme where he was Vice President of In Vitro Biology. In this role, Dr. Lillie was responsible for developing a scientific strategy for creating a sustainable, high value portfolio in rare diseases. He established a strong pipeline of small molecule drugs and supported the U.S. Food and Drug Administration’s approval of Eliglustat and acceptance of two investigational new drug applications. Previously, Dr. Lillie was Senior Director, In Vitro Biology at Sanofi Genzyme and, before that, he held roles of increasing responsibility at Millennium Pharmaceuticals, Inc. Earlier, he worked as Senior Director, Biology at Scriptgen Pharmaceuticals, and as co-founder at AMIRA, which was later sold to Repligen Corporation.
Dr. Lillie holds a Ph.D. in Biochemistry and Molecular Biology from Harvard University and B.A. in German Literature from Wesleyan University.
JONATHAN GILLIS, C.P.A.
Senior Vice President, Finance
Mr. Gillis joined OvaScience in June 2013. He brings 15 years of combined public accounting and industry experience to the OvaScience team. In his current role at the Company, Mr. Gillis oversees the Finance, Human Resources, Information Technology and Legal functions. He manages all SEC filings, budgets, works directly with the Audit and Compensation Committees, and is active with investor relations. He was also instrumental in multiple OvaScience public offerings. Previously, as the Senior Director of Global Finance and Operations at OvaScience, Mr. Gillis relocated to the United Kingdom and established the international headquarters for the Company. Prior to joining OvaScience, Mr. Gillis was a Senior Manager of External Reporting and Compliance at GFI Software where he managed SEC compliance and prepared the company for its initial public offering. Earlier in his career, Mr. Gillis was a Manager at PricewaterhouseCoopers, LLP, where he was responsible for all stages of integrated and non-integrated audit engagements with clients ranging from million-dollar private companies to multi-billion-dollar public companies.
Mr. Gillis is a certified public accountant. He holds a B.S. and a M.S. in Accounting from Babson College.
LOUIS S. VILLALBA
Senior Vice President, Corporate Development
Mr. Villalba joined OvaScience in November 2015. He brings more than 25 years of industry experience in developing and commercializing innovative therapies, and most recently served as the General Manager of North America at OvaScience. Prior to joining OvaScience, Mr. Villalba was Chief Business Officer at Evofem, an early stage company specializing in women’s health. In this role, he led portfolio development and managed strategic partnerships. Previously, he served as Global Vice President of Sales at Auxogyn, a TPG and Kleiner Perkins company that specializes in in vitro fertilization products. At Auxogyn, Mr. Villalba secured a key strategic partnership with Merck Serono for European commercialization. Earlier in his career, he served as the General Manager of Europe at Conceptus. He was part of the team that completed the $1.1 billion sale of the company to Bayer AG.
Mr. Villalba earned a B.A. in Business Management at Menlo College.